The global mifepristone market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Mifepristone is used in combination with misoprostol to end an early pregnancy that has been 70 days or less since the last menstrual period began. The global mifepristone market is growing due to the increasing cases of abortion on the global platform. According to World Health Organization (WHO) in November 2021, abortion is a common health intervention. It is safe when carried out using a method recommended by WHO. It also states that six out of 10 of all unintended pregnancies end in induced abortion. An estimation of 73 million induced abortions takes place globally every year. Therefore, the rising prevalence of abortion is driving the growth of the global mifepristone market.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Mifepristone at: https://orionmarketreports.com/request-sample/?id=103654&submit=Request+Sample%0D%0A
The North American region is anticipated to hold the major share in the global misoprostol market. This is due to the increasing number of abortion cases in this region. According to US Centre for Disease Control and Prevention in 2019, 629,898 legal induced abortions were reported in the country which accounts for 11.4 abortions per 1,000 women aged 15–44 years, and the abortion ratio was 195 abortions per 1,000 live births. Therefore, the rising abortion cases in this region are driving the growth of the mifepristone market in the North American region.
A full report of Global Mifepristone Market is available at: https://orionmarketreports.com/mifepristone-market/103654/
Some major players in the market include GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Mylan N.V., Lannett, and Horizon Therapeutics plc among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new drug launches, to stay competitive in the market. For instance, in December 2021, USFDA eliminates the restriction on abortion pills such as mifepristone drugs from the US market and announced the permanent availability of mifepristone drugs in the market.
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Mylan N.V., Lannett, and Horizon Therapeutics plc, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Mifepristone Market Report by Segment
By Application
- Pregnancy Drugs
- Gynecologic Surgery
- Others
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
